University Hospitals Cleveland Medical Center Feb 28 2025 A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the cholesterol drug fenofibrate (Triglide, Fibricor, Lipofen) as an investigational and potential treatment for patients with HPV+ cervical and HPV+ head and neck cancer (HNSCC). Published pre-clinical results show fenofibrate restores function of key tumor suppressor gene in these cancers. The group's pre-clinical